Evidence map›Paper›PMID 37777725›Full record

ArticleMalaria journal2023

A field bioassay for assessing ivermectin bio-efficacy in wild malaria vectors.

Kelly M Ominde, Yvonne Kamau, Jonathan Karisa, Martha N Muturi, Caroline Kiuru, Caroline Wanjiku, Lawrence Babu, Festus Yaah, Mercy Tuwei, Haron Musani and 5 more

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Kelly M OmindeDepartment of Biosciences, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya. kominde@kemri-wellcome.org.
Yvonne KamauDepartment of Biosciences, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Jonathan KarisaDepartment of Biosciences, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Martha N MuturiDepartment of Biosciences, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Caroline KiuruISGlobal, Barcelona, Spain.
Caroline WanjikuDepartment of Biosciences, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Lawrence BabuDepartment of Biosciences, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Festus YaahDepartment of Biosciences, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Mercy TuweiDepartment of Biosciences, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Haron MusaniDepartment of Biosciences, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Zedekiah OndiekiDepartment of Biosciences, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Simon MuriuDepartment of Biosciences, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Joseph MwangangiDepartment of Biosciences, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Carlos ChaccourISGlobal, Barcelona, Spain.
Marta F MaiaDepartment of Biosciences, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya. mmaia@kemri-wellcome.org.
Kenya Medical Research Institute · KEBarcelona Institute for Global Health · ESPwani University · KEUniversidad de Navarra · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIvermectin (IVM) mass drug administration is a candidate complementary malaria vector control tool. Ingestion of blood from IVM treated hosts results in reduced survival in mosquitoes. Estimating bio-efficacy of IVM on wild-caught mosquitoes requires they ingest the drug in a blood meal either through a membrane or direct feeding on a treated host. The latter, has ethical implications, and the former results in low feeding rates. Therefore, there is a need to develop a safe and effective method for IVM bio-efficacy monitoring in wild mosquitoes.

methodsInsectary-reared Anopheles gambiae s.s. were exposed to four IVM doses: 85, 64, 43, 21 ng/ml, and control group (0 ng/ml) in three different solutions: (i) blood, (ii) 10% glucose, (iii) four ratios (1:1, 1:2, 1:4, 1:8) of blood in 10% glucose, and fed through filter paper. Wild-caught An. gambiae s.l. were exposed to 85, 43 and 21 ng/ml IVM in blood and 1:4 ratio of blood-10% glucose mixture. Survival was monitored for 28 days and a pool of mosquitoes from each cohort sacrificed immediately after feeding and weighed to determine mean weight of each meal type.

resultsWhen administered in glucose solution, mosquitocidal effect of IVM was not comparable to the observed effects when similar concentrations were administered in blood. Equal concentrations of IVM administered in blood resulted in pronounced reductions in mosquito survival compared to glucose solution only. However, by adding small amounts of blood to glucose solution, mosquito mortality rates increased resulting in similar effects to what was observed during blood feeding.

conclusionBio-efficacy of ivermectin is strongly dependent on mode of drug delivery to the mosquito and likely influenced by digestive processes. The assay developed in this study is a good candidate for field-based bio-efficacy monitoring: wild mosquitoes readily feed on the solution, the assay can be standardized using pre-selected concentrations and by not involving treated blood hosts (human or animal) variation in individual pharmacokinetic profiles as well as ethical issues are bypassed. Meal volumes did not explain the difference in the lethality of IVM across the different meal types necessitating further research on the underlying mechanisms.

Indexed as

AnophelesInsecticidesMalariaAnimalsGlucoseHumansIvermectinMosquito ControlMosquito VectorsGlucoseInsecticidesIvermectinAnopheles gambiaeBio-efficacyField bioassayIvermectinKenyaMonitoringVector controlWild vectors

Identifiers

PMID37777725
PMCPMC10542238
OpenAlexW4387218458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.